Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Levis M, Perl A, Schiller G, Fathi AT, Roboz G, Wang ES, Altman J, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith C. Levis M, et al. Among authors: fathi at. Blood Adv. 2024 May 28;8(10):2527-2535. doi: 10.1182/bloodadvances.2023010619. Blood Adv. 2024. PMID: 38502195 Free PMC article. Clinical Trial.
Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT, Levis M. Fathi AT, et al. Expert Rev Hematol. 2009 Feb;2(1):17-26. doi: 10.1586/17474086.2.1.17. Expert Rev Hematol. 2009. PMID: 21082990 Review.
FLT3 inhibitors: a story of the old and the new.
Fathi A, Levis M. Fathi A, et al. Curr Opin Hematol. 2011 Mar;18(2):71-6. doi: 10.1097/MOH.0b013e3283439a03. Curr Opin Hematol. 2011. PMID: 21245757 Free PMC article. Review.
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Fathi AT, Arowojolu O, Swinnen I, Sato T, Rajkhowa T, Small D, Marmsater F, Robinson JE, Gross SD, Martinson M, Allen S, Kallan NC, Levis M. Fathi AT, et al. Leuk Res. 2012 Feb;36(2):224-31. doi: 10.1016/j.leukres.2011.07.011. Epub 2011 Jul 29. Leuk Res. 2012. PMID: 21802138 Free PMC article.
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Fathi AT, et al. Blood. 2012 Nov 29;120(23):4649-52. doi: 10.1182/blood-2012-06-438267. Epub 2012 Oct 16. Blood. 2012. PMID: 23074281 Free article.
FLT3 inhibitor-induced neutrophilic dermatosis.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. Fathi AT, et al. Blood. 2013 Jul 11;122(2):239-42. doi: 10.1182/blood-2013-01-478172. Epub 2013 May 17. Blood. 2013. PMID: 23687091 Free article.
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: fathi at. Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472813 Free PMC article. No abstract available.
175 results